Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
Merck & Co.’s long-running effort to land a punch on small cell lung cancer (SCLC) has racked up a small victory. | Merck & ...
Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, ...
GlobalData on MSN1d
NHS England to offer Daiichi Sankyo’s quizartinib for AMLThe UK Medicines and Healthcare products Regulatory Agency previously confirmed the asset’s safety and efficacy.
Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in ...
Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine ...
A quantitative continuous score identified patients with a TROP2 biomarker likely to respond to the antibody-drug conjugate, a study presented at WCLC showed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback